Paper Details

  1. Home
  2. Paper Details

Epidoxorubicin vs idarubicin containing regimens in intermediate and high grade non-Hodgkin's lymphoma: preliminary results of a multicentric randomized trial.

Author: AvanziniP, BrugiatelliM, CalleaV, CavannaL, De PasqualeA, Di PriscoA U, Di RienzoN, FedericoM, GobbiP G, SilingardiV

Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This report describes a prospective randomized trial on the treatment of aggressive and advanced non-Hodgkin's lymphoma (NHL) by the Italian Lymphoma Study Group (GISL), focusing on the efficacy of two Pro-MACE-CytaBom (P-C) derived protocols.
Paper Details　
Original Abstract of the Article :
In recent years many therapeutic regimens have been designed in order to improve response rate and response duration in non-Hodgkin's lymphoma (NHL). In 1991 the Italian Lymphoma Study Group (GISL) started a prospective randomized trial on treatment of aggressive and advanced NHL, focused on the eff...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/8314160

データ提供：米国国立医学図書館（NLM）

Epidoxorubicin vs Idarubicin in Non-Hodgkin's Lymphoma Treatment

This study investigates the efficacy of two different chemotherapy regimens, one containing epidoxorubicin and the other containing idarubicin, in the treatment of intermediate and high-grade non-Hodgkin's lymphoma (NHL). The study, conducted by the Italian Lymphoma Study Group (GISL), is a prospective randomized trial aimed at comparing the effectiveness of these two regimens derived from the Pro-MACE-CytaBom (P-C) protocol. The study aims to provide insights into the relative efficacy of these two chemotherapy approaches in treating aggressive NHL, offering valuable information for clinicians in selecting the most appropriate treatment options.

Chemotherapy Regimens: A Comparison in NHL Treatment

The study's findings provide valuable insights into the relative efficacy of epidoxorubicin-containing and idarubicin-containing regimens in treating aggressive NHL. The study's results offer a basis for clinicians to make informed decisions about selecting the most appropriate chemotherapy regimen for their patients based on individual characteristics and treatment goals.

Choosing the Right Treatment

Non-Hodgkin's lymphoma is a complex and challenging disease. This study emphasizes the importance of selecting the most appropriate chemotherapy regimen for each individual patient. By understanding the relative efficacy of different treatment approaches, clinicians can provide patients with the best possible care.

Dr.Camel's Conclusion

This research is like navigating a treacherous desert landscape, seeking the most effective path to treat non-Hodgkin's lymphoma. It reveals the complexities of chemotherapy regimens and the importance of choosing the most suitable approach for each patient. By carefully navigating these choices, we can offer hope and the best possible treatment outcomes for those battling this challenging disease.

Date :
  1. Date Completed 1994-03-24
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

8314160

DOI: Digital Object Identifier

8314160

Related Literature

Article Analysis
・Effective treatment of lymphoma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.